RT Journal Article
T1 Comparison of the management of Helicobacter pylori infection between the older and younger European populations
A1 Jonaitis, Paulius
A1 Nyssen, Olga P.
A1 Saracino, Ilaria Maria
A1 Fiorini, Giulia
A1 Vaira, Dino
A1 Perez-Aisa, Angeles
A1 Tepes, Bojan
A1 Castro-Fernandez, Manuel
A1 Pabon-Carrasco, Manuel
A1 Keco-Huerga, Alma
A1 Voynovan, Irina
A1 Lucendo, Alfredo J.
A1 Lanas, Angel
A1 Martinez-Dominguez, Samuel J.
A1 Alfaro Almajano, Enrique
A1 Rodrigo, Luis
A1 Vologzanina, Ludmila
A1 Jurecic, Natasa Brglez
A1 Denkovski, Maja
A1 Bujanda, Luis
A1 Mahmudov, Umud
A1 Leja, Marcis
A1 Lerang, Frode
A1 Babayeva, Gulustan
A1 Bordin, Dmitry S.
A1 Gasbarrini, Antonio
A1 Kupcinskas, Juozas
A1 Gridnyev, Oleksiy
A1 Rokkas, Theodore
A1 Marcos-Pinto, Ricardo
A1 Phull, Perminder S.
A1 Smith, Sinead M.
A1 Milivojevic, Vladimir
A1 Tonkic, Ante
A1 Boltin, Doron
A1 Buzas, Gyorgy Miklos
A1 Sembera, Stepan
A1 Simsek, Halis
A1 Matysiak-Budnik, Tamara
A1 Marlicz, Wojciech
A1 Venerito, Marino
A1 Boyanova, Lyudmila
A1 Doulberis, Michael
A1 Capelle, Lisette G.
A1 Cano-Catala, Anna
A1 Moreira, Leticia
A1 Megraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P.
A1 Jonaitis, Laimas
K1 Helicobacter pylori infection
K1 Eradication therapy
K1 Antibiotic resistance
K1 Older population
K1 Quadruple therapy
AB The prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment. The aim of the study was to evaluate the diagnostics and effectiveness of H. pylori eradication between the younger and older European populations. "European Registry on H. pylori Management (Hp-EuReg)" data from 2013 to 2022 were analyzed. Patients were divided into older (>= 60 years) and younger (18-59 years) groups. Modified intention-to-treat (mITT) and per-protocol (PP) analysis was performed. 49,461 patients included of which 14,467 (29%) were older-aged. Concomitant medications and penicillin allergy were more frequent among the older patients. Differences between younger and older populations were observed in treatment duration in first-line treatment and in proton pump inhibitors (PPIs) doses in second-line treatment. The overall incidence of adverse events was lower in the older adults group. The overall first-line treatment mITT effectiveness was 88% in younger and 90% in the older patients (p<0.05). The overall second-line mITT treatment effectiveness was 84% in both groups. The effectiveness of the most frequent first- and second-line triple therapies was suboptimal (<90%) in both groups. Optimal efficacy (>= 90%) was achieved by using bismuth and non-bismuth-based quadruple therapies. In conclusion, the approach to the diagnostics and treatment of H. pylori infection did not generally differ between younger and older patients. Main differences were reported in the concurrent medications, allergy to penicillin and adverse events both in first- and second-line treatment. Optimal effectiveness rates were mostly achieved by using bismuth and non-bismuth-based quadruple therapies. No clinically relevant differences in the effectiveness between the age groups were observed.
PB Nature Research: Scientific Reports
SN 2045-2322
YR 2023
FD 2023-10-23
LK https://hdl.handle.net/10668/28459
UL https://hdl.handle.net/10668/28459
LA en
NO Jonaitis P, Nyssen OP, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023 Oct 11;13(1):17235.
NO This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG)  and received support from the Spanish Association of Gastroenterology (AEG) and the Centro de Investigación  Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Te Hp-EuReg was co-funded by  the European Union programme HORIZON (grant agreement number 101095359) and supported by the UK  Research and Innovation (grant agreement number 10058099). Views and opinions expressed are however  those of the author(s) only and do not necessarily refect those of the European Union or the Health and Digitial  Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for  them. Te Hp-EuReg was co-funded by the European Union programme EU4Health (grant agreement number 101101252). Tis study was funded by Diasorin; however, clinical data were not accessible and the company  was not involved in any stage of the Hp-EuReg study (design, data collection, statistical analysis, or manuscript  writing). We want to thank Diasorin for their support.
DS RISalud
RD Apr 10, 2025